Development and validation of a high-performance liquid chromatography-electrospray ionization-MS/MS method for the simultaneous quantitation of levodopa and carbidopa in human plasma

被引:35
作者
Cesar, Isabela Costa [1 ,2 ]
Duarte Byrro, Ricardo Martins [1 ,2 ]
de Santana e Silva Cardoso, Fabiana Fernandes [2 ]
Mundim, Iram Moreira [2 ]
Teixeira, Leonardo de Souza [2 ]
Gomes, Sandro Antonio [2 ]
Bonfim, Ricardo Rodrigues [2 ]
Pianetti, Gerson Antonio [1 ]
机构
[1] Univ Fed Minas Gerais, Dept Prod Farmaceut, Fac Farm, BR-31270901 Belo Horizonte, MG, Brazil
[2] Inst Ciencias Farmaceut, BR-74175100 Goiania, Go, Brazil
来源
JOURNAL OF MASS SPECTROMETRY | 2011年 / 46卷 / 09期
关键词
levodopa; carbidopa; HPLC-ESI-MS/MS; plasma; pharmacokinetics; ELECTROCHEMICAL DETECTION; BIOAVAILABILITY; 3-O-METHYLDOPA; METABOLITES; DOPAMINE; DISEASE;
D O I
10.1002/jms.1973
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A sensitive and fast high-performance liquid chromatography-electrospray ionization-MS/MS method for the simultaneous quantitation of levodopa and carbidopa in human plasma was developed and validated. A simple protein precipitation step with perchloric acid was used for the cleanup of plasma, and methyldopa was added as an internal standard. The analyses were carried out using an ACE C(18) column (50 x 4.6mm i.d.; 5 mu m particle size) and a mobile phase consisting of 0.2% formic acid and acetonitrile (90: 10). The triple-quadrupole mass spectrometer equipped with an electrospray source in positive mode was set up in the selective reaction monitoring mode to detect the ion transitions m/z 198.1 -> m/z 107.0, m/z 227.2 -> m/z 181.0, and m/z 212.1 -> m/z 139.2 for levodopa, carbidopa, and methyldopa, respectively. The method was validated and proved to be linear, accurate, and precise over the range 50-5000 ng/mL for levodopa and 3-600 ng/mL for carbidopa. The proposed method was successfully applied in a pharmacokinetic study with a levodopa/carbidopa tablet formulation in healthy volunteers. Copyright (C) 2011 John Wiley & Sons, Ltd.
引用
收藏
页码:943 / 948
页数:6
相关论文
共 16 条
  • [1] Da Prada M, 1987, Eur Neurol, V27 Suppl 1, P9, DOI 10.1159/000116170
  • [2] Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility-an open-label, 6-week study
    Eggert, Karla
    Skogar, Orjan
    Amar, Khaled
    Luotonen, Liisa
    Kuoppamaki, Mikko
    Leinonen, Mika
    Nissinen, Helena
    Oertel, Wolfgang
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2010, 117 (03) : 333 - 342
  • [3] Food and Drug Administration, 2001, FDA GUID IND BIOAN M
  • [4] Simultaneous determination of L-dopa and its prodrug (S)-4-(2-acetamido-3-ethoxy-3-oxopropyl)-1,2-phenylene diacetate in rat plasma by high-performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study
    Jiang, Weizhe
    Lv, Li
    Zhou, Songyu
    Huang, Xingzhen
    Shi, Xiaoxia
    Lv, Cong
    Wu, Lingling
    Xu, Chongyao
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2010, 53 (03) : 751 - 754
  • [5] Modified high-performance liquid chromatography with electrochemical detection method for plasma measurement of levodopa, 3-O-methyldopa, dopamine, carbidopa and 3,4-dihydroxyphenyl acetic acid
    Karimi, Morvarid
    Carl, Juanita L.
    Loftin, Susan
    Perlmutter, Joel S.
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2006, 836 (1-2): : 120 - 123
  • [6] LEWITT PA, 1989, NEUROLOGY, V39, P45
  • [7] Quantitative analysis of levodopa, carbidopa and methyldopa in human plasma samples using HPLC-DAD combined with second-order calibration based on alternating trilinear decomposition algorithm
    Li, Shu-Fang
    Wu, Hai-Long
    Yu, Yong-Jie
    Li, Yuan-Na
    Nie, Jin-Fang
    Fu, Hai-Yan
    Yu, Ru-Qin
    [J]. TALANTA, 2010, 81 (03) : 805 - 812
  • [8] Müller T, 2009, PATIENT PREFER ADHER, V3, P51
  • [9] Pharmacokinetic optimisation in the treatment of Parkinson's disease - An update
    Nyholm, D
    [J]. CLINICAL PHARMACOKINETICS, 2006, 45 (02) : 109 - 136
  • [10] The scientific and clinical basis for the treatment of Parkinson disease (2009)
    Olanow, C. Warren
    Stern, Matthew B.
    Sethi, Kapil
    [J]. NEUROLOGY, 2009, 72 (21) : S1 - S136